June 7, 2007
Perceptronix Launches LungSign.Com: Providing Exciting Information on Innovative Technology That Brings New Hope to Those at Risk for Lung Cancer 
VANCOUVER, BRITISH COLUMBIA- June 7, 2007- Perceptronix Medical Inc. ("Perceptronix"), a private biotechnology company focused on detecting cancer at early stages, is pleased to announce the launch of its new website, www.lungsign.com. LungSign.com is designed to be a primary resource for patients and healthcare providers interested in the early detection of lung cancer.

June 6, 2007
MSFHR & FRSQ launch Interprovincial Directory of Researchers
Montreal and Vancouver, June 6, 2007 – A new Canadian online research resource was launched today, thanks to a joint effort between research support agencies in Quebec and British Columbia.

June 6, 2007
Aspreva announces Fast-Track designation granted by the FDA for CellCept in lupus nephritis
VICTORIA, June 6, 2007- Aspreva Pharmaceuticals Corporation (NASDAQ:ASPV; TSX: ASV) today announced that the U.S. Food and Drug Administration(FDA) has granted Fast Track designation for CellCept (mycophenolate mofetil,MMF) for the treatment of lupus nephritis. Aspreva is currently evaluatingCellCept for the treatment of lupus nephritis in a global phase III study.

June 4, 2007
Cardiome and Astellas Announce Positive Results From Act 2 Trial
Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. (“Astellas”) today announced results from their recently completed Phase 3 clinical study, called ACT 2. The trial evaluated the efficacy and safety of the intravenous formulation of vernakalant hydrochloride (“vernakalant (iv)”) for the treatment of patients who developed atrial fibrillation or atrial flutter between 24 hours and 7 days following coronary artery bypass graft (CABG) or valve replacement surgery. In the atrial fibrillation population, 47% of patients dosed with vernakalant (iv) experienced conversion to normal heart rhythm within 90 minutes, as compared to 14% of placebo patients, a statistically significant difference (p=0.0001).

June 4, 2007
Unique Award Program for Canadian Teachers Celebrating Biotechnology
Ottawa (June 4, 2007) – BIOTECanada and Biogen Idec offers a $10,000 award opportunity, recognizing teachers for their excellence in teaching biotechnology in the classroom.

June 4, 2007
Cardiome and Astellas Announce Positive Results from ACT 2 Trial
Vancouver, Canada and Deerfield, Illinois, USA, June 4, 2007 - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. (“Astellas”) today announced results from their recently completed Phase 3 clinical study, called ACT 2.

June 3, 2007
Study Presented at ASCO Shows Encouraging One-Year and Overall Survival Results for Phase I/II Trial of OGX-011 in Non-Small Cell Lung Cancer
VANCOUVER, BC and CARLSBAD, CA, June 3, 2007 - OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced encouraging preliminary data from a Phase I/II clinical trial of OGX-011 in first-line combination therapy for advanced non-small cell lung cancer (NSCLC).

June 2, 2007
Study Presented at ASCO Shows Encouraging Preliminary Results for Phase II Trial of OGX-011 in Advanced Prostate Cancer
VANCOUVER and CARLSBAD, CA, June 2, 2007 - OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced preliminary data from a Phase II clinical trial of OGX-011 in combination with docetaxel and prednisone in patients with metastatic hormone refractory prostate cancer (HRPC).

June 1, 2007
Eighth Annual PMC-Sierra Science Fair Fun Run Raises More Than $50,000 for B.C. Science Fair Students
VANCOUVER, British Columbia, June 1, 2007 -The eighth annual PMC-Sierra Science Fair Fun Run, which took place on Sunday, May 27 raised $50,000 and attracted over 1,300 runners. To date, the run has raised over $310,000 for The Dr. Michael Smith Science Fair Endowment in support of Science Fair programs across B.C. After the run, participants enjoyed free giveaways, live entertainment, face painting for children and free admission to the TELUS World of Science.

May 31, 2007
Cardiome to Present at Bear Stearns Conference
Cardiome Pharma Corp. today announced that Doug Janzen, President and Chief Business Officer, will present an overview of Cardiome at the Bear Stearns Boston Biotech Confab at 2:50pm EDT (11:50am PDT) on Thursday, June 7, 2007.

May 30, 2007
Angiotech Initiates European Trial Examining the Vascular Wrap Paclitaxel-Eluting Mesh for Dialysis Patients with End-Stage Renal Disease
Vancouver, BC, May 30, 2007- Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced the initiation of a European study evaluating the safety and efficacy of the Vascular Wrap paclitaxel-eluting mesh after surgical implantation with an ePTFE vascular graft in the upper extremity for hemodialysis vascular access.

May 30, 2007
Cardiome Announces Filing of New Drug Submission In Canada
Vancouver, Canada, May 30, 2007 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that Astellas Pharma Canada, Inc., an affiliate of its co-development partner, Astellas Pharma US, Inc., has filed a New Drug Submission (NDS) with the Therapeutic Products Directorate of Health Canada seeking Canadian approval to market the intravenous formulation of vernakalant hydrochloride (vernakalant (iv)), an investigational new drug for the acute conversion of atrial fibrillation.

May 29, 2007
Angiotech initiates European trial examining the Vascular Wrap(TM) paclitaxel-eluting mesh for Dialysis Patients with End-Stage Renal Disease
VANCOUVER, May 29, 2007- Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI,TSX: ANP), a global specialty pharmaceutical and medical device company, today announced the initiation of a European study evaluating the safety and efficacy of the Vascular Wrap(TM) paclitaxel-eluting mesh ("Vascular Wrap(TM)") after surgical implantation with an ePTFE vascular graft in the upper extremity for hemodialysis vascular (AV) access.

May 29, 2007
GenoLogics will Hold Live Auction in Support of Canary Derby
Victoria, BC, Canada - May 29, 2007 - GenoLogics Life Sciences Software (GenoLogics) today announced the Company will hold a live public auction on June 5, 2007 between 4:00 - 5:00pm, at the Vancouver Island Technology Park, to raise funds for the Canary Derby, a technology community soapbox race and fundraising drive to raise money for early detection cancer research through the BC Cancer Foundation.

May 28, 2007
GenoLogics Takes Home HR Excellence of the Year Award
Victoria, BC, Canada - May 28, 2007 - GenoLogics Life Sciences Software (GenoLogics) today announced the Company was recognized by the Vancouver Island Technology Community as an excellent place to work with an outstanding HR team. Last week, GenoLogics was the proud recipient of the Human Resources Excellence Award, at the VIATeC 2007 Technology Awards Dinner. In the current competitive hiring environment, a company’s culture and HR philosophy are crucial to attracting and retaining talented people. GenoLogics has developed a unique HR strategy with the goal of being recognized as one the best places to work in Canada.

May 28, 2007
Salmon conservation, cell research net new funding
Vancouver, BC- May 28, 2007- A pair of Simon Fraser University researchers poised to make breakthroughs in their fields will get more than anticipated in research funding from the Natural Sciences and Engineering Research Council (NSERC).

May 25, 2007
Centre for Drug and Research and Development Receives Additional $8 Million in Funding From the Province of BC
Vancouver, BC - May 25, 2007 The Centre for Drug Research and Development, a unique hybrid organization that helps health researchers collaborate, refine their discoveries and develop them for commercial use, received an additional $8 million in funding for its core facility. This investment matches the $8 million Canada Foundation for Innovation (CFI) grant CDRD received last November. It also comes on the heels of a $25 million funding grant from the Province of BC announced last month by Premier Gordon Campbell at the 2007 British Columbia Life Sciences Awards.

May 24, 2007
Aspreva completes expanded patient enrollment in phase III clinical trial for CellCept in pemphigus vulgaris
VICTORIA, British Columbia -May 24, 2007- Aspreva Pharmaceuticals Corporation today announced successful completion of patient enrollment in their global phase III clinical trial designed to assess the safety and efficacy of CellCept (mycophenolate mofetil) in association with corticosteroids to achieve remission in patients with active pemphigus vulgaris.

May 23, 2007
Reducol™ Product Range Expanded with Cholesterol-Lowering Rye Bread ~Kesko Launch Creates New Opportunities in European Functional Food Market~
Vancouver, British Columbia, May 23, 2007 – Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) announces Kesko Food Ltd (Kesko) of Finland has launched a cholesterol-lowering Rye Bread with Forbes Medi-Tech’s ingredient, Reducol™. The product launch further demonstrates Forbes’ ability to move quickly into new product markets and allows the Company to target other producers and retailers in Europe selling Rye Bread. The Rye Bread will be marketed under the ‘Pirkka’ premium private label brand name.

May 17, 2007
BIOTECanada Supports the New Science and Technology Strategy, Mobilizing Science and Tech to Canada's Advantage
OTTAWA, May 17, 2007- The national biotechnology industry association in Canada welcomed Canada's new national science and technology strategy announced today by Prime Minister Stephen Harper.

May 17, 2007
Angiotech receives European approval for Quill(R) SRS wound closure product- New Class of Wound Closure Product Expected to Launch in Europe Mid-Year
VANCOUVER, May 17, 2007 - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company today announced that is has received European approval for CE mark of its Quill(R) Self-Retaining System (SRS). Launched early in the year in the United States, Quill(R) SRS is expected to launch commercially in Europe mid-year.

May 15, 2007
Forbes Medi-Tech Reports Financial Results for the Quarter ended March 31, 2007 ~Revenue Up 122% Over Last Year~
Vancouver, Canada, May 15, 2007 – Forbes Medi-Tech Inc. (TSX:FMI; NASDAQ:FMTI) reports its financial results for the three months ended March 31, 2007. Comparative period for these statements is the three months ended March 31, 2006. All amounts are in Canadian Dollars unless otherwise noted.

May 15, 2007
10th Anniversary of Biotech 101 reflects “new” life sciences industry
May 15, 2007 – Vancouver “Biotechnology”, “genomes”, and “genetic engineering” are just a few of the terms that are heard more and more frequently in everyday news media, business dealings, and discussions, but what do these terms really mean? Luckily you do not need a doctorate to understand these and dozens of other new life science terms – you need just two days to take the Biotech 101 workshop offered by Life Sciences BC and BCIT.

May 11, 2007
Dr. Anthony Tolcher Joins Chemokine's Clinical Advisory Board
VANCOUVER, BRITISH COLUMBIA- May 5, 2007-- Chemokine Therapeutics Corp. (the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced that Dr. Anthony Tolcher, Director of Clinical Research at START (South Texas Accelerated Research Therapeutics), has joined its oncology Clinical Advisory Board. Comprised of leading oncologists and translational researchers, Chemokine's advisory boards play an important role in guiding and participating in Chemokine's clinical development programs.

May 10, 2007
Angiotech to Market Vascular Wrap/ePTFE Graft Combination Product Through its own European Sales and Distribution Networks
Vancouver, BC, May 10, 2007-Angiotech Pharmaceuticals (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has amended its agreement with Edwards Lifesciences Corporation, regarding the distribution of Angiotech's Vascular Wrap(TM) paclitaxel-eluting mesh/ePTFE graft combination product.

May 10, 2007
Cardiome to Release First Quarter Results
Cardiome Pharma Corp. today announced that it will report 2007 first quarter financial results on the morning of Friday, May 11, 2007. Cardiome will hold a teleconference call and webcast at 10:00am EDT (7:00am PDT) on that day to discuss the results.

May 8, 2007
Canadian and U.S. Biotechnology Companies Forging New Partnerships at the 2007 BIO International Convention- 80 Canadian companies gather at conference; establish new relationships with U.S.-based biotech firms
BOSTON, May 7, 2007- As 80 Canadian biotech companies cross the border into New England this week for the 2007 BIO International Convention, increased business and investment bonds between the two trading partners will be highlighted by a series of partnering events, and business and technology announcements.

May 8, 2007
Forbes Medi-Tech Announces Pharmavite Contract Renewal ~Key Reducol™ Customer Continues Contract and Continues to Expand Product Line with Reducol™-Based Products~
Vancouver, British Columbia, May 8, 2007– Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced it has extended its supply and licensing contract with Pharmavite LLC until mid 2008 for the continued sale of Reducol™, the branded cholesterol lowering ingredient in one of Pharmavite’s leading line of dietary supplements, Nature Made® CholestOff® and recently launched CholestOff® Complete.

May 7, 2007
Pacgen announces positive results from Phase I/II trial of novel anti-fungal drug
VANCOUVER, May 7, 2007- Pacgen Biopharmaceuticals Corporation ("Pacgen") (TSX-V: PGA) is pleased to report that topline results from its Phase I/II study of PAC-113, a novel antifungal, show it is generally safe, well-tolerated, and active in the treatment of oral Candida infection with clinical cure rates comparable to the current standard of care. Based on these results the Company plans to initiate a Phase IIb study to optimize PAC-113 dose and formulation.

May 7, 2007
Ondine Announces Clinical Advisory Board Member is Recipient of the 2007 IADR Periodontal Disease Research Award
VANCOUVER, May 7, 2007- Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) announces that Dr. Richard Darveau, a member of its Clinical Advisory Board, is the recipient of the 2007 Basic Research in Periodontal Disease Award from the International Association for Dental Research (IADR).

May 3, 2007
Key Patents Issued for ARCAD™ Instillate for the Prevention of Surgical Adhesions
Vancouver, British Columbia, May 3, 2007 – The University of British Columbia (UBC) and ARC Pharmaceuticals Inc. (ARC) today announced that key patents relating to ARC's lead product candidate, ARCAD™ Instillate, for the prevention and treatment of surgical adhesions, were recently issued or granted in several territories. The patents are assigned to UBC and ARC previously in-licensed these technologies through an exclusive worldwide license agreement with UBC.

May 3, 2007
Chemokine Therapeutics Annouces Results of Preclinical Study Conducted by M. D. Anderson Cancer Center on Its Anticancer Drug CTCE-9908
VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- May 03, 2007 -- Chemokine Therapeutics Corp. (the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced the results of a study conducted by The University of Texas M. D. Anderson Cancer Center to evaluate the ability of CTCE-9908 to inhibit the metastasis and growth of the primary tumor of a human breast cancer in preclinical models. The study concluded that treatment with the Company's CXCR4 antagonist, CTCE-9908, significantly reduced metastases and primary tumor growth in preclinical models of breast cancer. The effects of anti-metastasis could be due to inhibition of tumor cell homing; however, inhibition of primary tumor growth may indicate involvement of other mechanisms.